123 related articles for article (PubMed ID: 15757761)
1. Approaches to improving the kinetics of adenovirus-delivered genes and gene products.
Xu ZL; Mizuguchi H; Sakurai F; Koizumi N; Hosono T; Kawabata K; Watanabe Y; Yamaguchi T; Hayakawa T
Adv Drug Deliv Rev; 2005 Apr; 57(5):781-802. PubMed ID: 15757761
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy progress and prospects: adenoviral vectors.
St George JA
Gene Ther; 2003 Jul; 10(14):1135-41. PubMed ID: 12833122
[TBL] [Abstract][Full Text] [Related]
3. Use of multiply deleted adenovirus vectors to probe adenovirus vector performance and toxicities.
Amalfitano A
Curr Opin Mol Ther; 2003 Aug; 5(4):362-6. PubMed ID: 14513678
[TBL] [Abstract][Full Text] [Related]
4. Development of PEGylated adenovirus vector with targeting ligand.
Eto Y; Yoshioka Y; Mukai Y; Okada N; Nakagawa S
Int J Pharm; 2008 Apr; 354(1-2):3-8. PubMed ID: 17904316
[TBL] [Abstract][Full Text] [Related]
5. Advances towards targetable adenovirus vectors for gene therapy.
Einfeld DA; Roelvink PW
Curr Opin Mol Ther; 2002 Oct; 4(5):444-51. PubMed ID: 12435045
[TBL] [Abstract][Full Text] [Related]
6. The influence of adenovirus fiber structure and function on vector development for gene therapy.
Nicklin SA; Wu E; Nemerow GR; Baker AH
Mol Ther; 2005 Sep; 12(3):384-93. PubMed ID: 15993650
[TBL] [Abstract][Full Text] [Related]
7. Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications.
Parker AL; Nicklin SA; Baker AH
Curr Opin Mol Ther; 2008 Oct; 10(5):439-48. PubMed ID: 18830919
[TBL] [Abstract][Full Text] [Related]
8. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration.
Gao JQ; Eto Y; Yoshioka Y; Sekiguchi F; Kurachi S; Morishige T; Yao X; Watanabe H; Asavatanabodee R; Sakurai F; Mizuguchi H; Okada Y; Mukai Y; Tsutsumi Y; Mayumi T; Okada N; Nakagawa S
J Control Release; 2007 Sep; 122(1):102-10. PubMed ID: 17628160
[TBL] [Abstract][Full Text] [Related]
9. Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice.
Benihoud K; Esselin S; Descamps D; Jullienne B; Salone B; Bobé P; Bonardelle D; Connault E; Opolon P; Saggio I; Perricaudet M
Gene Ther; 2007 Mar; 14(6):533-44. PubMed ID: 17109009
[TBL] [Abstract][Full Text] [Related]
10. Promoters influence the kinetics of transgene expression following adenovector gene delivery.
Chen P; Tian J; Kovesdi I; Bruder JT
J Gene Med; 2008 Feb; 10(2):123-31. PubMed ID: 18064718
[TBL] [Abstract][Full Text] [Related]
11. Development and application of adenoviral vectors for gene therapy of cancer.
Zhang WW
Cancer Gene Ther; 1999; 6(2):113-38. PubMed ID: 10195879
[TBL] [Abstract][Full Text] [Related]
12. Innate immune response induced by gene delivery vectors.
Sakurai H; Kawabata K; Sakurai F; Nakagawa S; Mizuguchi H
Int J Pharm; 2008 Apr; 354(1-2):9-15. PubMed ID: 17640834
[TBL] [Abstract][Full Text] [Related]
13. [Application of gene therapy mediated by adenovirus vectors for bone trauma and bone disease].
Liu JZ; Ji ZL; Hu YY
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2003 May; 17(3):215-8. PubMed ID: 12822354
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice.
Varnavski AN; Calcedo R; Bove M; Gao G; Wilson JM
Gene Ther; 2005 Mar; 12(5):427-36. PubMed ID: 15647774
[TBL] [Abstract][Full Text] [Related]
15. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
16. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
Atencio IA; Grace M; Bordens R; Fritz M; Horowitz JA; Hutchins B; Indelicato S; Jacobs S; Kolz K; Maneval D; Musco ML; Shinoda J; Venook A; Wen S; Warren R
Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.
Ni S; Gaggar A; Di Paolo N; Li ZY; Liu Y; Strauss R; Sova P; Morihara J; Feng Q; Kiviat N; Touré P; Sow PS; Lieber A
Cancer Gene Ther; 2006 Dec; 13(12):1072-81. PubMed ID: 16874361
[TBL] [Abstract][Full Text] [Related]
18. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
19. Efficient gene transfer into murine pancreatic islets using adenovirus vectors.
Mukai E; Fujimoto S; Sakurai F; Kawabata K; Yamashita M; Inagaki N; Mizuguchi H
J Control Release; 2007 May; 119(1):136-41. PubMed ID: 17331612
[TBL] [Abstract][Full Text] [Related]
20. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.
Stoff-Khalili MA; Rivera AA; Glasgow JN; Le LP; Stoff A; Everts M; Tsuruta Y; Kawakami Y; Bauerschmitz GJ; Mathis JM; Pereboeva L; Seigal GP; Dall P; Curiel DT
Gene Ther; 2005 Dec; 12(23):1696-706. PubMed ID: 16034451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
